Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Change from baseline in BMI
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CSMS995B2403
NCT00076362
March 2004
Name | Location |
---|---|
Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
University of Iowa Hospitals and Clinics | Iowa City, Iowa 52242 |
Children's Hospital of Orange County | Orange, California 92668 |
Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania 15213 |
Phoenix Children's Hospital | Phoenix, Arizona 85016-7710 |
University of Colorado | Denver, Colorado 80217 |
Duke University Medical Center | Durham, North Carolina 27710 |
Washington University | St. Louis, Missouri 63110 |
Texas Children's Hospital | Houston, Texas |
University of California at San Francisco | San Francisco, California 94115 |
Miami Children'S Hopital | Miami, Florida 33155 |
Childrens Memorial Hospital | Chicago, Illinois 60614 |
St. Vincent Children's Center for Cancer and Blood Diseases | Indianapolis, Indiana 46260 |
U of Tennessee HELP Center | Memphis, Tennessee 38103 |
UT Southwestern Children's Medical Center of Dallas | Dallas, Texas 75390 |